Issue 2/2018
Content (20 Articles)
Hersintuzumab: A novel humanized anti-HER2 monoclonal antibody induces potent tumor growth inhibition
Mohammad Mehdi Amiri, Forough Golsaz-Shirazi, Tahereh Soltantoyeh, Reza Hosseini-Ghatar, Tannaz Bahadori, Jalal Khoshnoodi, Shadi Sadat Navabi, Samira Farid, Mohammad Hossein Karimi-Jafari, Mahmood Jeddi-Tehrani, Fazel Shokri
Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer
Lei Fang, Hao Wang, Peiling Li
Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer
Sang Eun Park, Ha-Gyeong Kim, Dong Eun Kim, Yoo Jung Jung, Yunlim Kim, Seong-Yun Jeong, Eun Kyung Choi, Jung Jin Hwang, Choung-Soo Kim
Antitumor activity of raloxifene-targeted poly(styrene maleic acid)-poly (amide-ether-ester-imide) co-polymeric nanomicelles loaded with docetaxel in breast cancer-bearing mice
Saeede Enteshari, Jaleh Varshosaz, Mohsen Minayian, Farshid Hassanzadeh
4EGI-1 represses cap-dependent translation and regulates genome-wide translation in malignant pleural mesothelioma
Arpita De, Blake A. Jacobson, Mark S. Peterson, Joe Jay-Dixon, Marian G. Kratzke, Ahad A. Sadiq, Manish R. Patel, Robert A. Kratzke
First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile
Giovanna Speranza, Larry Anderson, Alice P. Chen, Khanh Do, Michelle Eugeni, Marcie Weil, Larry Rubinstein, Eva Majerova, Jerry Collins, Yvonne Horneffer, Lamin Juwara, Jennifer Zlott, Rachel Bishop, Barbara A. Conley, Howard Streicher, Joseph Tomaszewski, James H. Doroshow, Shivaani Kummar
Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies
Xiaofei Zhou, John Nemunaitis, Shubham Pant, Todd M. Bauer, Manish Patel, John Sarantopoulos, A. Craig Lockhart, Daniel Goodman, Dirk Huebner, Diane R. Mould, Karthik Venkatakrishnan
Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies
Xiaofei Zhou, Shubham Pant, John Nemunaitis, A. Craig Lockhart, Gerald Falchook, Todd M. Bauer, Manish Patel, John Sarantopoulos, Michael Bargfrede, Andreas Muehler, Lakshmi Rangachari, Bin Zhang, Karthik Venkatakrishnan
Safety, tolerability, and pharmacokinetic profile of dabrafenib in Japanese patients with BRAF V600 mutation-positive solid tumors: a phase 1 study
Yutaka Fujiwara, Naoya Yamazaki, Yoshio Kiyohara, Shusuke Yoshikawa, Noboru Yamamoto, Arata Tsutsumida, Hiroshi Nokihara, Kenjiro Namikawa, Akihira Mukaiyama, Fanghong Zhang, Tomohide Tamura
Phase I dose escalation and pharmacokinetic study on the nanoparticle formulation of polymeric micellar paclitaxel for injection in patients with advanced solid malignancies
Meiqi Shi, Jing Sun, Jinsong Zhou, Hao Yu, Shaorong Yu, Guohao Xia, Li Wang, Yue Teng, Gangyi Liu, Chen Yu, Jifeng Feng, Yaling Shen
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
Evan Y. Yu, Susan L. Ellard, Sebastien J. Hotte, Joel R. Gingerich, Anthony M. Joshua, Martin E. Gleave, Kim N. Chi
A phase IIa study of HA-irinotecan, formulation of hyaluronic acid and irinotecan targeting CD44 in extensive-stage small cell lung cancer
Muhammad Alamgeer, D. Neil Watkins, Ilia Banakh, Beena Kumar, Daniel J. Gough, Ben Markman, Vinod Ganju
A phase II study of tipifarnib and gemcitabine in metastatic breast cancer
Clinton Yam, Rashmi K. Murthy, Vicente Valero, Janio Szklaruk, Girish S. Shroff, Carol J. Stalzer, Aman U. Buzdar, James L. Murray, Wei Yang, Gabriel N. Hortobagyi, Stacy L. Moulder, Banu Arun
The outcome of sorafenib monotherapy on hepatocellular carcinoma with portal vein tumor thrombosis
Yuan-Hung Kuo, I-Pei Wu, Jing-Houng Wang, Chao-Hung Hung, Kun-Ming Rau, Chien-Hung Chen, Kwong-Ming Kee, Tsung-Hui Hu, Sheng-Nan Lu
Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer
Xuenong Ouyang, Meiqi Shi, Fangwei Jie, Yuxian Bai, Peng Shen, Zhuang Yu, Xiuwen Wang, Cheng Huang, Min Tao, Zhehai Wang, Conghua Xie, Qi Wu, Yongqian Shu, Baohui Han, Fengchun Zhang, Yiping Zhang, Chunhong Hu, Xitao Ma, Yongjie Liang, Anlan Wang, Bing Lu, Yi Shi, Jinfei Chen, Zhixiang Zhuang, Jiejun Wang, Jianjin Huang, Changhui Wang, Chunxue Bai, Xin Zhou, Qiang Li, Feng Chen, Hao Yu, Jifeng Feng
Vinblastine and antihelmintic mebendazole potentiate temozolomide in resistant gliomas
Franciele Cristina Kipper, Andrew Oliveira Silva, André Luis Marc, Gláucia Confortin, Augusto Valadão Junqueira, Eliseu Paglioli Neto, Guido Lenz
Characteristics of patients with sorafenib-treated advanced hepatocellular carcinoma eligible for second-line treatment
Sadahisa Ogasawara, Tetsuhiro Chiba, Yoshihiko Ooka, Eiichiro Suzuki, Takahiro Maeda, Masayuki Yokoyama, Toru Wakamatsu, Masanori Inoue, Tomoko Saito, Kazufumi Kobayashi, Soichiro Kiyono, Masato Nakamura, Shingo Nakamoto, Shin Yasui, Akinobu Tawada, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Osamu Yokosuka, Naoya Kato
Association of Glutathione S-Transferase P-1 (GSTP-1) rs1695 polymorphism with overall survival in glioblastoma patients treated with combined radio-chemotherapy
Francesco Pasqualetti, Alessandra Gonnelli, Martina Cantarella, Durim Delishaj, Alessandro Molinari, Valerio Ortenzi, Francesco Carbone, Sabrina Montrone, Stefano Ursino, Sara Franceschi, Riccardo Morganti, Paola Orlandi, Teresa Di Desidero, Chiara Maria Mazzanti, Katia Zavaglia, Antonio Giuseppe Naccarato, Guido Bocci, Fabiola Paiar
Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature
Shoichi Deguchi, Koichi Mitsuya, Yoko Nakasu, Nakamasa Hayashi, Hirohisa Katagiri, Hideki Murata, Junji Wasa, Mitsuru Takahashi, Masahiro Endo
Gastrointestinal perforation related to lenvatinib, an anti-angiogenic inhibitor that targets multiple receptor tyrosine kinases, in a patient with metastatic thyroid cancer
Emi Date, Kunio Okamoto, Souichi Fumita, Hiroyasu Kaneda